May 09, 2025

Off-the-Shelf Natural Killer CAR T-Cell Therapy Shows Efficacy in Small Study of Relapsed or Refractory Blood Cancers

The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia.1 Over the past decade, other...

The ASCO Post

May 09, 2025

Building and Sharing Dietary Evidence in Cancer Care

Guest Editor’s Note: Several epidemiologic studies have shown an inverse association between healthy dietary patterns and the risk of chronic diseases including cancer. Patients are often interested i...

The ASCO Post

May 09, 2025

Study Shows Disparities in Diagnosing Endometrial Cancer in Women With Postmenopausal Bleeding

Angela Nolin, MD, a gynecologic oncology fellow at Duke University Health System in Durham, North Carolina, and colleagues conducted a multi-institutional study to determine whether racial difference...

The ASCO Post

May 09, 2025

FDA Approves Anti–PD-1 Antibody for Nasopharyngeal Cancer

The FDA has approved the humanized IgG1 monoclonal anti–PD-1 antibody penpulimab-kcqx with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic ...

The ASCO Post

May 09, 2025

Is Active Monitoring a Safe Option for Patients With Ductal Carcinoma In Situ?

With right-sizing treatment an aim of many treatment approaches in breast cancer today, ductal carcinoma in situ (DCIS), as well as its overtreatment, has become a potential target of change. Which pa...

The ASCO Post

May 09, 2025

Evolving Role of Surgical De-escalation for Endometrial, Ovarian, Cervical, and Vulvar Cancers

For more than a decade, the field of gynecologic oncology has witnessed a movement toward surgical de-escalation through the increased use of minimally invasive surgical techniques and sentinel lymph...

The ASCO Post

May 09, 2025

Therapy With a Tyrosine Kinase Inhibitor for EGFR-Variant Lung Adenocarcinoma: Lessons From Chronic Myeloid Leukemia?

Unresolved issues persist in treating EGFR-variant lung adenocarcinoma with tyrosine kinase inhibitors, contrasting with chronic myeloid leukemia (CML) therapy. Comparisons reveal complexities and uncertainties in patient selection, therapy monitoring, and treatment duration.

The ASCO Post

May 09, 2025

Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings

Two pivotal phase III trials presented at the 2024 ASH Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia, offering potentiall...

The ASCO Post

May 09, 2025

Richard Pazdur, MD, Honored With 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine

During the 2025 American Association for Cancer Research (AACR) Annual Meeting, Richard Pazdur, MD, accepted an award and gave remarks during the meeting’s Opening Ceremony.

The ASCO Post